Dividend-equivalent RSUs boost UL Solutions Inc. (NYSE: ULS) director stake

Rhea-AI Filing Summary

DOLLIVE JAMES P reported acquisition or exercise transactions in this Form 4 filing.

UL Solutions Inc. director James P. Dollive received 4 restricted stock units as a grant tied to dividend equivalent rights on existing awards. Each unit represents one share of Class A common stock. Following this grant, he holds 2,805 restricted stock units including accrued dividend equivalents, which will vest on the earlier of May 20, 2026 or the date of the annual meeting following the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DOLLIVE JAMES P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	4	$0.00	--

Holdings After Transaction: Restricted Stock Units — 2,805 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents accrual of dividend equivalent rights on restricted stock units held by the Reporting Person. The dividend equivalent rights accrued on restricted stock units held by the Reporting Person and vest proportionately with the restricted stock units to which they relate. The restricted stock units will vest on the earlier of May 20, 2026 or the date of the annual meeting following the grant date. Includes restricted stock units and all dividend equivalent rights that have accrued on such restricted stock units to date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOLLIVE JAMES P

(Last) (First) (Middle)

C/O UL SOLUTIONS INC.

333 PFINGSTEN ROAD

(Street)

NORTHBROOK IL 60062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UL Solutions Inc. [ ULS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/12/2026		A		4(2)		(3)	(3)	Class A Common Stock	4	$0	2,805(4)	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. Represents accrual of dividend equivalent rights on restricted stock units held by the Reporting Person.

3. The dividend equivalent rights accrued on restricted stock units held by the Reporting Person and vest proportionately with the restricted stock units to which they relate. The restricted stock units will vest on the earlier of May 20, 2026 or the date of the annual meeting following the grant date.

4. Includes restricted stock units and all dividend equivalent rights that have accrued on such restricted stock units to date.

	/s/ Ryan Robinson, Attorney-in-Fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UL Solutions (ULS) report for James P. Dollive?

UL Solutions reported that director James P. Dollive received 4 restricted stock units as a grant. These arose from dividend equivalent rights on his existing restricted stock units and represent additional contingent rights to receive Class A common shares, increasing his equity-based compensation position.

How many UL Solutions (ULS) RSUs does James P. Dollive hold after this transaction?

After this transaction, James P. Dollive holds 2,805 restricted stock units and related dividend equivalent rights. This figure includes the 4 newly granted units arising from dividend equivalents, reflecting his total outstanding contingent rights to receive UL Solutions Class A common stock under these awards.

What do the new UL Solutions (ULS) restricted stock units represent for James P. Dollive?

Each new restricted stock unit represents a contingent right to receive one share of UL Solutions’ Class A common stock. The 4 additional units result from dividend equivalent rights accrued on previously granted units, effectively mirroring cash dividends in the form of additional equity-based awards.

How did dividend equivalent rights affect James P. Dollive’s UL Solutions (ULS) holdings?

Dividend equivalent rights on James P. Dollive’s existing UL Solutions restricted stock units accrued as 4 additional units. These rights track dividends that would have been paid on common shares and are credited as extra restricted stock units, which vest along with the underlying awards over time.

When will James P. Dollive’s new UL Solutions (ULS) RSUs vest?

The restricted stock units, including those from dividend equivalent rights, will vest on the earlier of May 20, 2026 or the date of the annual meeting following the grant. Vesting must occur before the contingent rights convert into actual Class A common shares for Dollive.

Are James P. Dollive’s UL Solutions (ULS) dividend equivalent RSUs tied to existing awards?

Yes. The 4 additional restricted stock units come from dividend equivalent rights on existing restricted stock units held by James P. Dollive. These dividend equivalents vest proportionately with the original units, aligning their vesting schedule and maintaining consistent treatment with the underlying equity awards.